La presentazione è in caricamento. Aspetta per favore

La presentazione è in caricamento. Aspetta per favore

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria.

PubblicatoViola Moro Modificato 9 anni fa

Presentazioni simili

Presentazione sul tema: "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria."— Transcript della presentazione:

1 Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, Concetta Conticello, Davide Rossi, Valeria Magarotto, Pellegrino Musto, Luana Boccadifuoco, Massimo Offidani, Paola Omedé, Fabiana Gentilini, Giovannino Ciccone, Giulia Benevolo, Mariella Genuardi, Vittorio Montefusco, Stefania Oliva, Tommaso Caravita, Paola Tacchetti, Mario Boccadoro, Pieter Sonneveld, and Antonio Palumbo Blood Volume 124(1):63-69 July 3, 2014 ©2014 by American Society of Hematology

2 Kaplan-Meier analysis of time to response, showing proportion of responding patients achieving their best response over time. Sara Bringhen et al. Blood 2014;124:63-69 ©2014 by American Society of Hematology

3 Kaplan-Meier analysis of time to events data. Sara Bringhen et al. Blood 2014;124:63-69 ©2014 by American Society of Hematology

Scaricare ppt "Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria."

Presentazioni simili

Faculty of Medicine and Psychology University of Rome “La Sapienza”

Faculty of Medicine and Psychology University of Rome “La Sapienza”
Renaissance Artists By John Spencer Donatello Leonardo Raphael Michelangelo.

Renaissance Artists By John Spencer Donatello Leonardo Raphael Michelangelo.
CMS RPC R&D for phase 2 Two types of upgrades proposed for the CMS RPC muon system: 1.Aging and longevity: installed in 2007, must continue to operate.

CMS RPC R&D for phase 2 Two types of upgrades proposed for the CMS RPC muon system: 1.Aging and longevity: installed in 2007, must continue to operate.
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia by Andrea Pession, Riccardo Masetti,

Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia by Andrea Pession, Riccardo Masetti,
CMS RPC R&D for phase 2 Two types of upgrades proposed for the CMS RPC muon system: 1.Aging and longevity: installed in 2007, must continue to operate.

CMS RPC R&D for phase 2 Two types of upgrades proposed for the CMS RPC muon system: 1.Aging and longevity: installed in 2007, must continue to operate.
A controlled-source experiment to investigate the origin of wavefield polarization in fault zones Giuseppe Di Giulio 1, Antonio Rovelli 2, Fabrizio Cara.

A controlled-source experiment to investigate the origin of wavefield polarization in fault zones Giuseppe Di Giulio 1, Antonio Rovelli 2, Fabrizio Cara.
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the.

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the.
Opposing functions of Ki- and Ha-Ras genes in the regulation of redox signals Mariarosaria Santillo, Paolo Mondola, Rosalba Serù, Tiziana Annella, Silvana.

Opposing functions of Ki- and Ha-Ras genes in the regulation of redox signals Mariarosaria Santillo, Paolo Mondola, Rosalba Serù, Tiziana Annella, Silvana.
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation by Mauro Di Ianni, Franca Falzetti, Alessandra Carotti, Adelmo.

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation by Mauro Di Ianni, Franca Falzetti, Alessandra Carotti, Adelmo.
With the participation of and supported by I Contratti di fiume per la buona governance di acqua e territorio Massimo Bastiani Coordinatore del Tavolo.

With the participation of and supported by I Contratti di fiume per la buona governance di acqua e territorio Massimo Bastiani Coordinatore del Tavolo.
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella.

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella.
Additional chromosomal abnormalities in Philadelphia- positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party.

Additional chromosomal abnormalities in Philadelphia- positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party.
Identification of a New Locus for Medullary Cystic Disease, on Chromosome 16p12 Francesco Scolari, Daniela Puzzer, Antonio Amoroso, Gianluca Caridi, Gian.

Identification of a New Locus for Medullary Cystic Disease, on Chromosome 16p12 Francesco Scolari, Daniela Puzzer, Antonio Amoroso, Gianluca Caridi, Gian.
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma Luigi.

Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma Luigi.
Problematiche nutrizionali nell ʼ adulto e nell ʼ anziano: paziente con BPCO e paziente con diabete. Dr. V. Emanuele.

Problematiche nutrizionali nell ʼ adulto e nell ʼ anziano: paziente con BPCO e paziente con diabete. Dr. V. Emanuele.
Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano,

Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano,
PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression.

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression.
Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation.

Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation.
Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo.

Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo.
Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis by Fausto Castagnetti, Gabriele.

Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis by Fausto Castagnetti, Gabriele.

Presentazioni simili

Annunci Google